Prothena Plc share price today

(PRTA)

Prothena Plc share price is $15.74 & ₹1,342.15 as on 27 Dec 2024, 2.30 'hrs' IST

$15.74

▲

0.34

(2.21%)

Market is closed - opens 8 PM, 27 Dec 2024

View live Prothena Plc share price in Dollar and Rupees. Guide to invest in Prothena Plc from India. Also see the sentimental analysis on Indian investors investing in Prothena Plc. Get details on the Indian mutual funds that are investing in Prothena Plc. Get Analyst recommendations and forecasts along with all the Prothena Plc's financials.

Prothena Plc share price movements

Today's Low: $14.89
Today's High: $15.78
$15.74
5.4%
Downside
Day's Volatility :5.64%
Upside
0.25%
52 Weeks Low: $11.70
52 Weeks High: $41.55
$15.74
25.67%
Downside
52 Weeks Volatility :71.84%
Upside
62.11%

Prothena Plc Returns

Period	Prothena Corporation Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	-23.19%	-9.0%	0.0%
6 Months	-25.39%	-4.6%	0.0%
1 Year	-59.97%	3.0%	0.0%
3 Years	-66.3%	0.0%	-21.1%

Prothena Plc Key Statistics

in dollars & INR

Previous Close	$15.4
Open	$15.25
Today's High	$15.78
Today's Low	$14.89
Market Capitalization	$828.7M
Today's Volume	$245.8K
52 Week High	$41.545
52 Week Low	$11.7
Revenue TTM	$133.4M
EBITDA	$-167.2M
Earnings Per Share (EPS)	$-2.46
Profit Margin	-98.86%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-22.9%

How to invest in Prothena Plc from India?

It is very easy for Indian residents to invest directly in Prothena Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Prothena Plc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Prothena Plc or PRTA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Prothena Plc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Prothena Plc shares which would translate to 0.054 fractional shares of Prothena Plc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Prothena Plc, in just a few clicks!

Returns in Prothena Plc for Indian investors in Rupees

Investment Value

₹1,00,000

Prothena Plc investment value today

Current value as on today

₹43,240

Returns

₹56,760

(-56.76%)

Returns from Prothena Plc Stock

₹59,085 (-59.09%)

Dollar Returns

₹2,325 (+2.33%)

Indian investors sentiment towards Prothena Plc

142%

Period: Sep 27, 2024 to Dec 26, 2024. Change in 30 Days versus previous period

Search volume for Prothena Plc on INDmoney from India has grown in the last 30 days as on Dec 27, 2024. 142% more investors are searching Prothena Plc in the last 30 days versus the previous period.

Global Institutional Holdings in Prothena Plc

EcoR1 Capital, LLC
21.53%
FMR Inc
14.99%
Wellington Management Company LLP
7.77%
BlackRock Inc
7.17%
T. Rowe Price Associates, Inc.
7.10%
Palo Alto Investors, LLC
3.23%

Analyst Recommendation on Prothena Plc

Buy

76%Buy

23%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Prothena Plc(by analysts ranked 0 to 5 stars)

Based on 17 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Prothena Plc

What analysts predicted

Upside of 216.07%

Current:

$15.74

Target:

$49.75

Insights on Prothena Plc

Price Movement
In the last 7 days, PRTA stock has moved down by -3.8%
Decreasing Revenue
Revenue is down for the last 2 quarters, 132.01M → 970.0K (in $), with an average decrease of 99.3% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 66.88M → -59.00M (in $), with an average decrease of 188.2% per quarter
PRTA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 27.2% return, outperforming this stock by 88.9%
PRTA vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 25.2% return, outperforming this stock by 93.4%
Price to Sales
ForPRTA every $1 of sales, investors are willing to pay $6.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.7 for every $1 of sales.

Prothena Plc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$955.0K	↓ 96.53%
Net Income	$-155.6M	↑ 1.57%
Net Profit Margin	-16.3K%	↓ 15741.07%

	FY19	Y/Y Change
Revenue	$814.0K	↓ 14.76%
Net Income	$-77.7M	↓ 50.09%
Net Profit Margin	-9.5K%	↑ 6755.28%

	FY20	Y/Y Change
Revenue	$853.0K	↑ 4.79%
Net Income	$-111.1M	↑ 43.08%
Net Profit Margin	-13.0K%	↓ 3487.15%

	FY21	Y/Y Change
Revenue	$200.6M	↑ 23414.3%
Net Income	$67.0M	↓ 160.26%
Net Profit Margin	33.39%	↑ 13063.17%

	FY22	Y/Y Change
Revenue	$53.9M	↓ 73.13%
Net Income	$-116.9M	↓ 274.62%
Net Profit Margin	-216.95%	↓ 250.34%

	FY23	Y/Y Change
Revenue	$91.4M	↑ 69.5%
Net Income	$-147.0M	↑ 25.72%
Net Profit Margin	-160.91%	↑ 56.04%

	Q2 FY23	Q/Q Change
Revenue	$4.0M	↑ 85.29%
Net Income	$-54.6M	↑ 16.5%
Net Profit Margin	-1.4K%	↑ 802.21%

	Q3 FY23	Q/Q Change
Revenue	$84.9M	↑ 2011.62%
Net Income	$21.9M	↓ 140.13%
Net Profit Margin	25.81%	↑ 1384.23%

	Q4 FY23	Q/Q Change
Revenue	$316.0K	↓ 99.63%
Net Income	$-67.5M	↓ 408.01%
Net Profit Margin	-21.4K%	↓ 21378.97%

	Q1 FY24	Q/Q Change
Revenue	$50.0K	↓ 84.18%
Net Income	$-72.2M	↑ 7.06%
Net Profit Margin	-144.5K%	↓ 123124.84%

	Q2 FY24	Q/Q Change
Revenue	$132.0M	↑ 263928.0%
Net Income	$66.9M	↓ 192.59%
Net Profit Margin	50.67%	↑ 144528.67%

	Q3 FY24	Q/Q Change
Revenue	$970.0K	↓ 99.27%
Net Income	$-59.0M	↓ 188.21%
Net Profit Margin	-6.1K%	↓ 6133.25%

	FY18	Y/Y Change
Profit	$955.0K	↓ 96.53%

	FY19	Y/Y Change
Profit	$-50.0M	↓ 5337.91%

	FY20	Y/Y Change
Profit	$853.0K	↓ 101.71%

	FY21	Y/Y Change
Profit	$200.6M	↑ 23414.3%

	FY22	Y/Y Change
Profit	$53.9M	↓ 73.13%

	FY23	Y/Y Change
Profit	$-129.2M	↓ 339.68%

	Q2 FY23	Q/Q Change
Profit	$2.2M	↑ 440.98%

	Q3 FY23	Q/Q Change
Profit	$82.6M	↑ 3621.96%

	Q4 FY23	Q/Q Change
Profit	$-14.0M	↓ 116.92%

	Q1 FY24	Q/Q Change
Profit	$-837.0K	↓ 94.01%

	Q2 FY24	Q/Q Change
Profit	$74.5M	↓ 9001.31%

	Q3 FY24	Q/Q Change
Profit	$970.0K	↓ 98.7%

	FY18	Y/Y Change
Operating Cash Flow	$-28.3M	↓ 78.45%
Investing Cash Flow	$-1.7M	↓ 50.89%
Financing Cash Flow	$40.0M	↓ 75.79%

	FY19	Y/Y Change
Operating Cash Flow	$-53.0M	↑ 87.33%
Investing Cash Flow	$-547.0K	↓ 68.36%
Financing Cash Flow	$228.0K	↓ 99.43%

	FY20	Y/Y Change
Operating Cash Flow	$-80.4M	↑ 51.72%
Investing Cash Flow	$-196.0K	↓ 64.17%
Financing Cash Flow	$215.0K	↓ 5.7%

	FY21	Y/Y Change
Operating Cash Flow	$92.6M	↓ 215.23%
Investing Cash Flow	$-575.0K	↑ 193.37%
Financing Cash Flow	$190.3M	↑ 88426.51%

	FY22	Y/Y Change
Operating Cash Flow	$-108.8M	↓ 217.51%
Investing Cash Flow	$-464.0K	↓ 19.3%
Financing Cash Flow	$241.5M	↑ 26.86%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-44.9M	↓ 5.33%
Investing Cash Flow	$-771.0K	↑ 1506.25%
Financing Cash Flow	$18.6M	↓ 20.01%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$9.5M	↓ 121.18%
Investing Cash Flow	$-442.0K	↓ 42.67%
Financing Cash Flow	$2.7M	↓ 85.44%

Prothena Plc Technicals Summary

Sell

Neutral

Buy

Prothena Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Prothena Plc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Prothena Corporation Plc	-3.02%	-25.39%	-59.97%	-66.3%	-2.35%
Regeneron Pharmaceuticals, Inc.	-5.35%	-32.02%	-18.97%	11.91%	91.19%
Biontech Se	-5.46%	42.02%	7.95%	-52.72%	226.93%
Alnylam Pharmaceuticals, Inc.	-4.13%	0.1%	24.29%	44.19%	112.09%
Vertex Pharmaceuticals Incorporated	-12.14%	-12.92%	-0.27%	83.92%	86.41%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Prothena Corporation Plc	35.44	NA	0.8	-2.24	-0.23	-0.16	NA	9.93
Regeneron Pharmaceuticals, Inc.	17.67	17.67	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Prothena Corporation Plc	Buy	$828.7M	-2.35%	35.44	-98.86%
Regeneron Pharmaceuticals, Inc.	Buy	$78.5B	91.19%	17.67	33.61%
Biontech Se	Buy	$27.4B	226.93%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	112.09%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$105.1B	86.41%	32.84	-4.51%

About Prothena Plc

prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f

Organization	Prothena Plc
Employees	173
CEO	Dr. Gene G. Kinney Ph.D.
Industry	Health Technology

Management People of Prothena Plc

Name	Title
Dr. Gene G. Kinney Ph.D.	President, CEO & Director
Mr. Tran B. Nguyen M.B.A.	CFO & Chief Strategy Officer
Mr. Brandon S. Smith	Chief Operating Officer
Ms. Carol D. Karp	Chief Regulatory Officer
Ms. Karin L. Walker CPA	Chief Accounting Officer & Controller
Dr. Wagner M. Zago Ph.D.	Chief Scientific Officer
Mr. Mark C. Johnson C.F.A.	Vice President of Investor Relations
Mr. Michael J. Malecek	Chief Legal Officer
Mr. David A. Ford	Chief People Officer
Dr. Chad J. Swanson Ph.D.	Chief Development Officer

Important FAQs about investing in Prothena Plc from India :

What is Prothena Plc share price today?

Prothena Plc share price today stands at $15.74, Open: $15.25 ; Previous Close: $15.40 ; High: $15.78 ; Low: $14.89 ; 52 Week High: $41.55 ; 52 Week Low: $11.70. The stock opens at $15.25, after a previous close of $15.40. The stock reached a daily high of $15.78 and a low of $14.89, with a 52-week high of $41.55 and a 52-week low of $11.70.

Can Indians buy Prothena Plc shares?

Yes, Indians can invest in the Prothena Plc (PRTA) from India.

With INDmoney, you can buy Prothena Plc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Prothena Plc at zero transaction cost.

How can I buy Prothena Plc shares from India?

It is very easy to buy Prothena Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Prothena Plc be purchased?

Yes, you can buy fractional shares of Prothena Plc with INDmoney app.

What are the documents required to start investing in Prothena Plc stocks?

To start investing in Prothena Plc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.